Andrea Allmendinger
Chief Scientific Officer
Prof. Dr. Andrea Allmendinger is the Chief Scientific Officer at ten23 health AG, a Swiss CDMO specializing in the technical development and manufacturing of parenteral drug products. Before joining ten23 health in 2021, she held the position of Principal Scientist in Pharmaceutical Development for parenteral products at Roche in Basel from 2010 to 2021.
She studied Pharmacy at the University of Heidelberg, Germany, and University College London, UK, and earned her Ph.D. in Pharmaceutical Sciences from the University of Basel, Switzerland.
In 2025, she was appointed Professor of Pharmaceutical Technology at the University of Freiburg. Her research focuses on novel parenteral drug formulations and device solutions to enhance product stability and usability. She is an expert in the development of freeze-dried parenteral formulations, with extensive expertise in lyophilization process development, optimization, and technology transfer.
From 2021 to 2024, she also served as Editor-in-Chief of the AAPS Open journal.
DAY 2: June 6th, 2025
SESSION: RFID-based unit level traceability: A case study for visual inspection of pre-filles syringes
◆ Case study on visual inspection: Implementation of unit-level traceability for prefilled syringes using RFID tags in a GMP parenteral fill/finish environment.
◆ Real-world performance insights: Quantitative and qualitative comparison of conventional versus RFID-enabled systems, demonstrating measurable improvements in processing time for manual visual inspection.
◆ Technological impact: Overview of the key benefits and implementation challenges of RFID-based unit-level traceability.
